eISSN: 3087-405X editor@aimjournals.com
All Journals
Submit your article

International Research Journal of Medical Sciences and Health Care

Open Access Peer Review International
Open Access

Clinical And Pathogenetic Significance Of Nos3 Gene C-786t Polymorphism In Diabetic Foot Syndrome: A Literature Review

DOI https://doi.org/10.55640/irjmshc-v03i01-03
PDF
Musashaykhov H.T. 1 , Khamidov D.A. 1 , Musashaykhov U.Kh. 1 ,
4 Andijan State Medical Institute, Uzbekistan
4 Andijan State Medical Institute, Uzbekistan
4 Andijan State Medical Institute, Uzbekistan

Abstract

Diabetic foot syndrome (DFS) represents a complex and severe complication of diabetes mellitus, involving peripheral neuropathy, micro- and macrovascular dysfunction, and infection. Endothelial dysfunction plays a central role in its pathogenesis. One of the key regulators of endothelial function is endothelial nitric oxide synthase (eNOS), encoded by the NOS3 gene. The C-786T promoter polymorphism of NOS3 has been studied as a potential genetic determinant of nitric oxide (NO) bioavailability and vascular response. This review synthesizes current evidence on the association of the NOS3 C-786T polymorphism with DFS severity, ulcer development, healing outcomes, and risk stratification in diabetic patients. Overall, findings suggest that NOS3 C-786T polymorphism may influence endothelial NO synthesis, contribute to impaired microcirculation, and serve as a genetic marker for individualized prognostic assessment and therapeutic stratification in DFS.

Keywords

Diabetic foot syndrome, NOS3 gene, C-786T polymorphism, endothelial dysfunction

References

📄 International Diabetes Federation. IDF Diabetes Atlas. 10th ed. Brussels: IDF; 2021.
📄 Boulton A.J.M., Armstrong D.G., Albert S.F., Frykberg R.G., Hellman R., Kirkman M.S., et al. Comprehensive foot examination and risk assessment. Diabetes Care. 2008;31(8):1679–1685.
📄 Edmonds M., Foster A. Managing the Diabetic Foot. 3rd ed. Oxford: Wiley-Blackwell; 2014.
📄 Casas J.P., Bautista L.E., Humphries S.E., Hingorani A.D. Endothelial nitric oxide synthase gene polymorphisms and cardiovascular disease: a HuGE review. Circulation. 2004;109(11):1359–1365.
📄 Förstermann U., Sessa W.C. Nitric oxide synthases: regulation and function. European Heart Journal. 2012;33(7):829–837.
📄 Tesauro M., Cardillo C. Obesity, blood vessels and metabolic syndrome. Acta Physiologica. 2011;203(1):279–286.
📄 Moncada S., Higgs A. The L-arginine–nitric oxide pathway. The New England Journal of Medicine. 1993;329(27):2002–2012.
📄 Cheng J., Jiang J., Liu Y., Chen H. Association between endothelial nitric oxide synthase gene polymorphisms and diabetic microvascular complications: a meta-analysis. Molecular Biology Reports. 2014;41(4):2295–2304.
📄 Wang X.L., Mahaney M.C., Sim A.S., Wang J., Wang J., Blangero J., et al. Genetic contribution of the endothelial nitric oxide synthase gene to plasma nitric oxide levels. Arteriosclerosis, Thrombosis, and Vascular Biology. 1997;17(11):3147–3153.
📄 Stehouwer C.D.A., Lambert J., Donker A.J.M., van Hinsbergh V.W.M. Endothelial dysfunction and pathogenesis of diabetic angiopathy. Cardiovascular Research. 1997;34(1):55–68.
📄 Hinchliffe R.J., Brownrigg J.R.W., Apelqvist J., Boyko E.J., Fitridge R., Mills J.L., et al. IWGDF guidance on the diagnosis, prognosis and management of peripheral artery disease in patients with foot ulcers in diabetes. Diabetes/Metabolism Research and Reviews. 2016;32(S1):37–44.